Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin-23 and interleukin-17A, respectively, and are effective in adult patients with moderate-to-severe plaque psoriasis but have different dosing regimens. OBJECTIVES: To compare directly the efficacy and safety of risankizumab vs. secukinumab over 52 weeks. METHODS: IMMerge was an international, phase III, multicentre, open-label, efficacy-assessor-blinded, active-comparator study, in which adult patients with chronic, moderate-to-severe plaque psoriasis were randomized in a 1 : 1 ratio to treatment with risankizumab 150 mg or secukinumab 300 mg. Primary efficacy endpoints were the proportions of patients achieving ≥ 90% improvement from baseline in Psoriasis Area and Severity Index (PASI 90) at week 16 (noninferiority comparison with margin of 12%) and week 52 (superiority comparison). RESULTS: In total 327 patients from nine countries were treated with risankizumab (n = 164) or secukinumab (n = 163). Risankizumab was noninferior to secukinumab in the proportion of patients achieving PASI 90 at week 16 [73·8% vs. 65·6%; difference of 8·2%, 96·25% confidence interval (CI)-2·2 to 18·6; within the 12% noninferiority margin] and superior to secukinumab at week 52 (86·6% vs. 57·1%; difference of 29·8%, 95% CI 20·8-38·8; P < 0·001), thus meeting both primary endpoints. All secondary endpoints (PASI 100, static Physician's Global Assessment 0 or 1, and PASI 75) at week 52 demonstrated superiority for risankizumab vs. secukinumab (P < 0·001). No new safety concerns were identified. CONCLUSIONS: At week 52, risankizumab demonstrated superior efficacy and similar safety with less frequent dosing compared with secukinumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
A graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Wolf, N., Quaranta, M., Prescott, N. J., Allen, M., Smith, R., Burden, A. D., Worthington, J., Griffiths, C. E. M., Mathew, C. G., Barker, J. N., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.053595 · Cited by 171
Cited by
Gordon, K. B., Foley, P., Krueger, J. G., Pinter, A., Reich, K., Vender, R., Vanvoorden, V., Madden, C., White, K., Cioffi, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00126-4 · Cited by 295
Self-citationThe Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192
Data extraction for evidence synthesis using a large language model: A proof-of-concept study
Gartlehner, G., Kahwati, L., Hilscher, R., Thomas, I., Kugley, S., Crotty, K., Viswanathan, M., Nussbaumer‐Streit, B., Booth, G., Erskine, N., et al. (2024) · Research Synthesis Methods · doi:10.1002/jrsm.1710 · Cited by 164
Megna, M., Tommasino, N., Potestio, L., Battista, T., Ruggiero, A., Noto, M., Fabbrocini, G., & Genco, L. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2081655 · Cited by 90
“Their efficacy and safety have been shown by several clinical trials, such as VOYAGE-1 and VOYAGE-2 (3,4), NAVIGATE (5), and ECLIPSE (6) for guselkumab, reSURFACE 1 and reSURFACE 2 (7,8) for tildrakizumab, UltIMMa-1 e UltIMMa-2 (9,10), IMMERGE (11), and IMMVENT (12) for risankizumab.”
MethodPerformance of two large language models for data extraction in evidence synthesis
Konet, A., Thomas, I., Gartlehner, G., Kahwati, L., Hilscher, R., Kugley, S., Crotty, K., Viswanathan, M., & Chew, R. (2024) · Research Synthesis Methods · doi:10.1002/jrsm.1732 · Cited by 79
Metadata
- Authors
- Warren, R. B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., & Paul, C.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-09-06
- Volume
- 184
- Issue
- 1
- Pages
- 50-59
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W3037060742
- Cited by
- 211
- References
- 4
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.